Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study
Cancer Medicine · 2024
DOI: 10.1002/cam4.7208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Shuai Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center, Wuxi, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Chemoradiotherapy, ErbB Receptors, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cohort and Clinical Research Program of Wuxi Medical Center, Nanjing Medical University, Medical Innovation Team of Wuxi, Top Medical Expert Team of 2021 Taihu Talent Plan Project.
Abstract (Originalsprache)
Objective
To elucidate the potential benefits of combining radiotherapy and epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) for individuals with Stage IV lung adenocarcinoma (LUAD) harboring either exon 19 deletion ( 19‐Del ) or exon 21 L858R mutation ( 21‐L858R ).
Methods
In this real‐world retrospective study, 177 individuals with Stage IV LUAD who underwent EGFR‐TKIs and radiotherapy at Shandong Cancer Hospital from June 2012 to August 2017 were included. The main focus of this real‐world study was overall survival (OS).
Results
The clinical characteristics of patients with Stage IV LUAD harboring 19‐Del were similar to those harboring 21‐L858R ( p > 0.05). Overall, the patients had a median OS (mOS) of 32.0 months (95% confidence interval [CI]: 28.6–35.5). Subsequently, multivariate analysis indicated that both EGFR mutations and thoracic radiotherapy were independent predictors of OS ( p = 0.001 and 0.013). Furthermore, subgroup analysis highlighted a longer OS for the 19‐Del group compared to the 21‐L858R group, especially when EGFR‐TKIs were combined with bone metastasis or thoracic radiotherapy (mOS: 34.7 vs. 25.1 months and 51.0 vs. 29.6 months; p = 0.0056 and 0.0013, respectively). However, no significant differences were found in OS when considering patients who underwent brain metastasis radiotherapy (mOS: 34.7 vs. 25.1 months; p = 0.088).
Conclusions
Patients with Stage IV LUAD harboring 19‐Del experience a notably prolonged OS following combined therapy with EGFR‐TKIs and radiotherapy, while this OS benefit is observed despite the absence of substantial differences in the clinical characteristics between the 19‐Del and 21‐L858R groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center, Wuxi, China.
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- The Affiliated Children's Hospital of Jiangnan University, Wuxi School of Medicine, Wuxi, China.
- Department of oncology, Shengli Oilfield Central Hospital, Dongying, China.
ORCID-Profile: Dong Hua
Förderung
- Cohort and Clinical Research Program of Wuxi Medical Center, Nanjing Medical University
- Medical Innovation Team of Wuxi
- Top Medical Expert Team of 2021 Taihu Talent Plan Project
- Major Program of Wuxi Medical Center, Nanjing Medical University
Zitieren
APA
Liang, S., Wang, H., Zhang, Y., Tian, H., Li, C., & Hua, D. (2024). Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study. Cancer Medicine. https://doi.org/10.1002/cam4.7208
Vancouver
Liang S, Wang H, Zhang Y, Tian H, Li C, Hua D. Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study. Cancer Medicine. 2024. doi:10.1002/cam4.7208
BibTeX
@article{Liang2024,
author = {Liang, Shuai and Wang, Hanyu and Zhang, Yingyun and Tian, Haixia and Li, Chengming and Hua, Dong},
title = {Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7208}
}
EUVIMED